Rationally designed dendritic silica nanoparticles for oral delivery of exenatide

Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in managing the disease, but they cannot reverse the...

ver descrição completa

Detalhes bibliográficos
Autor principal: Abeer, MM (author)
Outros Autores: Meka, AK (author), Pujara, N (author), Kumeria, T (author), Strounina, E (author), Nunes, R (author), Costa, A (author), Sarmento, B (author), Hasnain, SZ (author), Ross, BP (author), Popat, A (author)
Formato: article
Idioma:eng
Publicado em: 2019
Assuntos:
Anti-diabetic peptides
Exenatide
Large pore silica nanoparticles
Oral delivery
Texto completo:https://hdl.handle.net/10216/137931
País:Portugal
Oai:oai:repositorio-aberto.up.pt:10216/137931

Texto Completo

https://hdl.handle.net/10216/137931

Registros relacionados